Skip to main content

Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.

Publication ,  Conference
Badruddoja, MA; Reardon, DA; Akabani, G; Friedman, AH; Friedman, HS; Rich, JN; Quinn, JA; Penne, K; Vredenburgh, JJ; Bigner, DD
Published in: JOURNAL OF CLINICAL ONCOLOGY
July 15, 2004

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

July 15, 2004

Volume

22

Issue

14

Start / End Page

124S / 124S

Location

New Orleans, LA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

40th Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Badruddoja, M. A., Reardon, D. A., Akabani, G., Friedman, A. H., Friedman, H. S., Rich, J. N., … Bigner, D. D. (2004). Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 22, pp. 124S-124S). New Orleans, LA: AMER SOC CLINICAL ONCOLOGY.
Badruddoja, M. A., D. A. Reardon, G. Akabani, A. H. Friedman, H. S. Friedman, J. N. Rich, J. A. Quinn, K. Penne, J. J. Vredenburgh, and D. D. Bigner. “Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.” In JOURNAL OF CLINICAL ONCOLOGY, 22:124S-124S. AMER SOC CLINICAL ONCOLOGY, 2004.
Badruddoja MA, Reardon DA, Akabani G, Friedman AH, Friedman HS, Rich JN, et al. Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 124S-124S.
Badruddoja MA, Reardon DA, Akabani G, Friedman AH, Friedman HS, Rich JN, Quinn JA, Penne K, Vredenburgh JJ, Bigner DD. Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 124S-124S.

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

July 15, 2004

Volume

22

Issue

14

Start / End Page

124S / 124S

Location

New Orleans, LA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

40th Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences